Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families, but also received good FDA news regarding its treatment for Alzheimer's Disease. The company announced that Lomecel B has been granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA, which we believe improves prospects for the company through development and/or partnerships.
